<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230334</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 79112 (old system)</org_study_id>
    <secondary_id>HEMMPD0001</secondary_id>
    <nct_id>NCT00230334</nct_id>
  </id_info>
  <brief_title>Phase II Gleevec Idiopathic Hypereosinophilic Syndrome</brief_title>
  <official_title>Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven E. Coutre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the safety and efficacy of Gleevec&quot; in idiopathic&#xD;
      hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic&#xD;
      benefit of Gleevec&quot; in HES.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated by PI due to insufficient accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 12, 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">December 29, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the hematologic response rate of imatinib in patients with HES.</measure>
  </primary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Eosinophilia</condition>
  <condition>Hypereosinophilic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- At study entry, absolute peripheral blood eosinophil count greater&#xD;
        than upper limit of normal at the laboratory where the analysis is performed.&#xD;
&#xD;
          -  Patients must have symptomatic disease, e.g. signs or symptoms of organ involvement&#xD;
             related to eosinophilia. Examples include pulmonary, cardiac, GI, or central nervous&#xD;
             system disease, hepatomegaly, splenomegaly, or skin disease.&#xD;
&#xD;
          -  BCR-ABL-negative by PCR.&#xD;
&#xD;
          -  Patients are imatinib-naive.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Ability to swallow capsules.&amp;#xA; Exclusion Criteria:- Pregnant or nursing women.&#xD;
             Patients of childbearing potential must have a negative pregnancy test prior to&#xD;
             initiation of study drug. Male and female patients of reproductive potential must&#xD;
             agree to employ an effective barrier method of birth control during the study and for&#xD;
             3 months following discontinuation of study drug.&#xD;
&#xD;
          -  Serum creatinine &gt;2.0.&#xD;
&#xD;
          -  Total serum bilirubin &gt;2.0 mg/dl. AST(SGOT) and ALT (SGPT) more than 2.5 x the upper&#xD;
             limit of normal range (ULN) at the laboratory where the analyses is performed.&#xD;
&#xD;
          -  Presence of clonal T-lymphocyte population by PCR or southern blotting.&#xD;
&#xD;
          -  ECOG Performance Status Score &gt; or = to 3.&#xD;
&#xD;
          -  Busulfan within 6 weeks of starting treatment.&#xD;
&#xD;
          -  IFN-a within 14 days of starting treatment.&#xD;
&#xD;
          -  Low dose cytosine-arabinoside or vincristine within 14 days of starting treatment.&#xD;
&#xD;
          -  Hydroxyurea within 1 day of starting treatment.&#xD;
&#xD;
          -  Prednisone or other immunosuppressives (e.g. azathioprine, cyclosporine-A) within 14&#xD;
             days of starting treatment.&#xD;
&#xD;
          -  AML/ALL-type induction chemotherapy within 4 weeks of starting treatment&#xD;
&#xD;
          -  Persistent peripheral blood count toxicity of grade 2 or higher after receiving&#xD;
             AML/ALL-type induction chemotherapy.&#xD;
&#xD;
          -  Treatment with other investigational agents within 28 days of starting treatment.&#xD;
&#xD;
          -  History of non-compliance to medical regimens.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (Grade 3 / 4 New York Heart&#xD;
             Association Criteria), unstable angina pectoris or cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  History of HIV-positivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E Coutre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 28, 2005</study_first_submitted>
  <study_first_submitted_qc>September 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven E. Coutre</investigator_full_name>
    <investigator_title>Professor of Medicine (Hematology) at the Stanford University Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

